Journal of Cystic Fibrosis
Volume 2, Issue 1 , Pages 29-34 , March 2003

Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients

  • Tim W.R. Lee

      Affiliations

    • Leeds Regional Paediatric Cystic Fibrosis Centre, St James's Hospital, Leeds, UK
    • Corresponding Author InformationCorresponding author. Tel: +44-113-206-4966; fax: +44-113-206-7011
    • ,
  • Keith G. Brownlee

      Affiliations

    • Leeds Regional Paediatric Cystic Fibrosis Centre, St James's Hospital, Leeds, UK
    • ,
  • Steven P. Conway

      Affiliations

    • Leeds Regional Paediatric Cystic Fibrosis Centre, St James's Hospital, Leeds, UK
    • ,
  • Miles Denton

      Affiliations

    • Department of Microbiology, The Leeds Teaching Hospitals NHS Trust, Leeds, UK
    • ,
  • James M. Littlewood

      Affiliations

    • Leeds Regional Paediatric Cystic Fibrosis Centre, St James's Hospital, Leeds, UK

References 

  1. FitzSimmons S. The cystic fibrosis foundation patient registry report. Pediatr Pulmonol. 1996;21:267–275
  2. Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonisation with Pseudomonas aeruginosa. J Pediatr. 1990;116:714–719
  3. Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonisation on lung function and anthropomorphic variables in children with cystic fibrosis. Pediatr Pulmonol. 1995;19:10–15
  4. Kosorok MR, Zeng L, West SH, et al.  Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol. 2001;32:277–287
  5. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992;12:158–161
  6. Brett MM, Simmonds EJ, Ghonheim ATM, Littlewood JM. The value of serum IgG titres against Pseudomonas aeruginosa in the management of early infection in cystic fibrosis. Arch Dis Child. 1992;67:1086–1088
  7. Frederiksen B, Koch C, Høiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974–1995). Pediatr Pulmonol. 1999;28:159–166
  8. Ballmann M, Rabsch P, von der Hardt H. Long term follow-up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax. 1998;53(9):732–737
  9. Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991;338:725–726
  10. Döring G, Conway SP, Heijerman HG, Hodson ME, Høiby N, Smyth A, et al. Antibiotic treatment against Pseudomonas aeruginosa in cystic fibrosis: A European consensus. Eur Respir J. 2000;16(4):749–767
  11. Denton M, Wilcox MH. Antimicrobial treatment of pulmonary colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. J Antimicrob Chemother. 1997;40(4):468–474
  12. Cheng K, Smyth RL, Govan JR, et al.  Spread of a beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996;348:639–642
  13. Pedersen SS, Koch C, Høiby N, Rosenthal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother. 1986;17:505–516
  14. Høiby N. Microbiology of Cystic Fibrosis. In:  Hodson ME,  Geddes DM editor. Cystic Fibrosis. London: Arnold; 1999;p. 75–98
  15. Bryman A, Cramer D. Quantitative data analysis for social scientists. London: Routledge; 1990;
  16. Nixon GM, Armstrong DS, Carzino R, et al.  Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J. Pediatr. 2001;138(5):699–704
  17. Standards of Care: Standards for the clinical care of children and adults with cystic fibrosis in the UK. The Cystic Fibrosis Trust's Clinical Standards and Accreditation Group. Cystic Fibrosis Trust, London, UK, 2001
  18. De Boeck K, Alifier M, Vandeputte S. Sputum induction in young cystic fibrosis patients. Eur Respir J. 2000;16(1):91–94
  19. Shwachman H, Kulczycki LL. Long-term study of one hundred and five patients with cystic fibrosis. Am J Dis Child. 1958;96:6–15
  20. Conway SP, Pond MN, Bowler I, et al.  The chest radiograph in cystic fibrosis: A new scoring system compared with the Chrispin–Norman and Brasfield Scores. Thorax. 1994;49:860–862
  21. Polgar G, Promadhat V. Pulmonary function testing in children. Philadelphia: W.B. Saunders; 1971;
  22. Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch. Dis. Child. 1995;73:25–29
  23. Burns JL, Gibson RL, McNamara S, et al.  Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis. 2001;183(3):444–452
  24. Høiby N. Prospects for the prevention and control of Pseudomonas aeruginosa infection in children with cystic fibrosis. Paediatric Drugs. 2000;2(6):451–463
  25. Hodson ME. Clinical studies of rhDNase in moderately and severely affected patients with cystic fibrosis—an overview. Respiration. 1995;62(1):29–30
  26. Pseudomonas aeruginosa infection: prevention and infection control. Report of the United Kingdom Cystic Fibrosis Trust's Infection Control Group. Cystic Fibrosis Trust, London, UK, 2001

PII: S1569-1993(02)00141-8

doi: 10.1016/S1569-1993(02)00141-8

Journal of Cystic Fibrosis
Volume 2, Issue 1 , Pages 29-34 , March 2003

Article Tools